The importance of microvascular dysfunction in patients with chronic thromboembolic pulmonary hypertension

The importance of microvascular dysfunction in patients with chronic thromboembolic pulmonary hypertension - Microcascular dysfunction in patients with CTEPH

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000059714

Enrollment

Registered

2025-11-17

Start date

2025-11-17

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic thromboembolic pulmonary hypertension

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients diagnosed with CTEPH 2. Patients judged eligible for BPA treatment 3. Patients aged 20 years or older at the time of obtaining consent

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
The following measurements will be performed three months after the final BPA: - Right heart catheterization (PAWP, PAP, RVP, RAP, CO, CI)- Exercise stress right heart catheterization (mPAP/CO slope, PAWP/CO slope)	—

Secondary

Measure	Time frame
1. Patient Basic Information: WHO-FC, emPHasis-10 2. Blood Test Results: Improvement in BNP and Nt-ProBNP 3. Imaging Results: Improvement in pulmonary blood flow on chest contrast CT and lung perfusion scintigraphy 4. Physiological Tests: Pulmonary function tests , transthoracic echocardiography, cardiopulmonary exercise test, 6-minute walk test 5. Blood Gas Tests (arterial, venous) 6. BPA Treatment Details (number of sessions, maximum balloon size, amount of contrast agent used, radiation exposure, fluoroscopy time)	—

Measure

Time frame

1. Patient Basic Information: WHO-FC, emPHasis-10 2. Blood Test Results: Improvement in BNP and Nt-ProBNP 3. Imaging Results: Improvement in pulmonary blood flow on chest contrast CT and lung perfusion scintigraphy 4. Physiological Tests: Pulmonary function tests , transthoracic echocardiography, cardiopulmonary exercise test, 6-minute walk test 5. Blood Gas Tests (arterial, venous) 6. BPA Treatment Details (number of sessions, maximum balloon size, amount of contrast agent used, radiation exposure, fluoroscopy time)

—

Countries

Japan

Contacts

Public ContactTomohiro Yamaguchi

Osaka Metropolitan University Graduate School of Medicine Cardiovascular Medicine

tomohiro.y.1987@gmail.com06-6645-3801

Outcome results